Atea Pharmaceuticals
AVIR
103 hedge funds and large institutions have $158M invested in Atea Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 36 increasing their positions, 37 reducing their positions, and 11 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3% less repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 37
3% less funds holding
Funds holding: 106 → 103 (-3)
4.8% less ownership
Funds ownership: 66.7% → 61.9% (-4.8%)
16% less capital invested
Capital invested by funds: $189M → $158M (-$30.4M)
27% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 11
48% less call options, than puts
Call options by funds: $23K | Put options by funds: $44K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$1.14M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$644K |
| 3 |
CM
CM Management
Gulf Breeze,
Florida
|
+$624K |
| 4 |
PLC
Peapod Lane Capital
Bedford Hills,
New York
|
+$385K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$343K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$11.2M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.27M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$851K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$614K |
| 5 |
BlackRock
New York
|
-$372K |
AVIR Hedge Fund Activity: Q1 2025 in Review
103 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Atea Pharmaceuticals (AVIR) for Q1 2025, worth a combined $158M — down 16% from $189M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of AVIR and 8 opened new positions — a net loss of 3 holders — while 37 trimmed existing stakes and 36 added.
The largest buyer was JP Morgan Chase, adding an estimated $1.14M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $11.2M sold.
- 103 institutional investors held Atea Pharmaceuticals (AVIR) as of Q1 2025, down from 106 in Q4 2024.
- Funds reported $158M of Atea Pharmaceuticals stock for Q1 2025, down 16% quarter-over-quarter.
- 8 funds opened new Atea Pharmaceuticals positions in Q1 2025 and 11 closed out, a net change of -3 holders.
- The largest Atea Pharmaceuticals buyer in Q1 2025 was JP Morgan Chase, an estimated $1.14M added.
- The largest Atea Pharmaceuticals seller in Q1 2025 was EcoR1 Capital, an estimated $11.2M sold.
Based on aggregated 13F filings for Q1 2025.